Cite
HARVARD Citation
Laccetti, A. et al. (2021). Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer medicine. pp. 2341-2349. [Online].